Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
37.16
-2.39 (-6.04%)
At close: May 16, 2025, 4:00 PM
36.00
-1.16 (-3.12%)
After-hours: May 16, 2025, 6:46 PM EDT
Monopar Therapeutics Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Monopar Therapeutics stock ranges from a low of $40 to a high of $76. The average analyst price target of $59.5 forecasts a 60.12% increase in the stock price over the next year.
Price Target: $59.50 (+60.12%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 1, 2025.
Analyst Ratings
The average analyst rating for Monopar Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 0 | 1 | 1 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 5 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +7.64% | Apr 1, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $76 | Buy | Initiates | $76 | +104.52% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $22 → $40 | Strong Buy | Maintains | $22 → $40 | +7.64% | Jan 22, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $72 | Buy | Initiates | $72 | +93.76% | Jan 10, 2025 |
Financial Forecast
Revenue This Year
n/a
from 77.96M
Revenue Next Year
n/a
EPS This Year
-2.65
from -4.11
EPS Next Year
-1.98
from -2.65
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 5.7M | 46.7M | ||
| Avg | n/a | 3.1M | 23.9M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,390.4% | ||
| Avg | - | - | 663.3% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.98 | -1.76 | 0.76 | ||
| Avg | -2.65 | -1.98 | -0.31 | ||
| Low | -3.47 | -2.16 | -1.49 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.